Project Grant R43HD084019

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $298,646 to Anvil Diagnostics Inc. aims to develop a rapid diagnostic test for sepsis-causing pathogens in plasma samples. The proposed DNA-based technology seeks to comprehensively identify and quantify a wide range of pathogens in under 4 hours from small blood volumes, critical capabilities for detecting sepsis in newborns. The research objectives include developing an...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award supports the development of a novel device that can rapidly and automatically extract pathogen DNA from whole blood samples to enable faster diagnosis of sepsis. The $274,858 award to New England Hemolytics, Inc., with a project period from September 1, 2024 to February 28, 2025, will fund the testing and optimization of this technology across common sepsis-causing pathogens. The...

This Small Business Innovation Research (SBIR) Phase II Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $1,250,000 to Prompt Diagnostics, Inc. to develop an automated, point-of-care diagnostic device for infections caused by Treponema pallidum. The device is designed to accelerate pathogen detection and reduce the interval between testing and treatment, which may help lower rates of perinatal...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $300,000 to Baebies, Inc. to develop a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs). The goal is to create a fully automated, CLIA-waived testing platform that can differentiate active STI infections from non-viable infections within 20 minutes, enabling clinicians to...

This $1,000,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of Helixbind's RAPID/BSI, an automated, culture-free system for the rapid identification of bloodstream infections directly from blood samples. The project aims to complete verification and validation activities to prepare for FDA regulatory clearance of this breakthrough diagnostic technology....

Chosen Diagnostics Inc., a minority-owned, woman-owned small business, has been awarded a $999,749 Cooperative Agreement from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program. The funding will support the development of reagents and reference standards for an innovative diagnostic test to quantify host biomolecules related to gut health in premature infants. This work aims to enable early and accurate detection of necrotizing enterocolitis...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) Project Grant award of $274,362 to RT Microdx Inc. focuses on developing a novel molecular diagnostic platform for detecting respiratory diseases like strep throat. The platform aims to provide the accuracy of lab-based tests for use by non-healthcare professionals in non-clinical settings, enabling rapid and reliable pathogen detection at home. This is expected to reduce the burden on...

This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the federal Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), will develop living biosensors for detecting and analyzing DNA at the single-base level without requiring sample purification or specialized equipment. The $257,807 award to the University of California, San Diego will demonstrate the use of these biosensors to rapidly...

This $1,413,007 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development and evaluation of the CRISPR-TB diagnostic tool for detecting tuberculosis (TB) in children under 5 years old. The University of Washington is the primary grantee and will lead a large prospective study of 400 children with suspected TB. The project aims to expand upon prior successful...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $490,093 to the University of Maryland, College Park to develop a rapid, culture-free technology for antibiotic susceptibility testing. The award will fund the creation of a microfluidic platform that can isolate bacteria directly from whole blood, identify the pathogen, and evaluate its response to antibiotics...